KRAS and neoplasm: Its upregulation is strongly associated with aggressive tumor features (VI, PNI, advanced stage, low differentiation) and molecular alterations (pMMR status, MLH1-deficient, KRAS mutations, HER-2 positive, PD-L1 CPS negative, and high KI-67 expression).